soul trial oral semaglutide cardiovascular outcomes results 2024 2025 (Semaglutide triaL) in individuals with SOUL: Oral Semaglutide Bests Usual
Description
Semaglutide (Wegovy) produces around 14.9% average body weight loss over 68 weeks in the STEP 1 trial
Results As shown in Table 3, patients generally reported a high level of satisfaction with the aesthetic outcomes of the procedure
2.5 Statistical analysis We pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) using the DerSimonian and Laird random-effects model, which accounts for between study heterogeneity
In other cases, temporarily pausing or reducing the dose may help your eyes stabilize
Were in this together, and well get you the right tools to achieve a slimmer, healthier you
